In a report released today, James Quigley from Goldman Sachs maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of DKK1,025.00. The company’s shares closed yesterday at DKK752.99.
According to TipRanks, Quigley is an analyst with an average return of -3.7% and a 39.45% success rate.
In addition to Goldman Sachs, Novo Nordisk also received a Buy from Deutsche Bank ‘s Emmanuel Papadakis in a report issued yesterday. However, on November 18, UBS maintained a Hold rating on Novo Nordisk (LSE: 0QIU).
0QIU market cap is currently DKK3305.4B and has a P/E ratio of 35.08.
Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is neutral on the stock.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Novo Nordisk (0QIU) Company Description:
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 20% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read More on GB:0QIU:
- RBC sees little cause for concern over CMS’ proposed part D GLP-1 coverage rule
- Trump threatens tariffs, Zoom reports Q3 beat: Morning Buzz
- Weight loss drugmakers in spotlight as White House proposes coverage
- Trump Trade: Carmakers slip after 25% tariff threat on Mexico, Canada
- Amgen weight loss data ‘underwhelms,’ says Deutsche Bank
